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Summary
Background: The prevalence of obesity and its metabolic consequences has dramatically increased in
the last two decades urging physicians to find a reliable definition for early detection, treatment and possibly
prevention of metabolic syndrome (MS). MS could be diagnosed in adult patients in the presence of a large
waist circumference and 2 of the following features: high serum triglycerides, low serum high-density
lipoprotein cholesterol, high blood pressure and high fasting glucose. The definition of MS in children is more
problematic, and the potential role of its single components on metabolic risk remains largely undefined.
Recent evidence strongly suggests not only a relationship between non-alcoholic fatty liver disease (NAFLD)
and MS in obese children, adolescents and adults, but also the key role exerted by liver fat deposition in the
pathogenesis of MS.
Conclusion: We propose that NAFLD should be routinely checked in obese subjects because early
lifestyle changes may be effective in reducing the overall risk of MS.
Keywords: Insulin resistance metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic
steatohepatitis.
Introduction
According to the International Diabetes Federation
(IDF), metabolic syndrome (MS) could be diagnosed
in adult patients in the presence of a large waist
circumference and 2 of the following features: high
serum triglycerides, low serum high-density lipopro-
tein (HDL) cholesterol, high blood pressure and high
fasting glucose (1). Large waist circumference was
also considered as one of the features necessary to
establish the diagnosis of MS (2). A definition of MS
similar to that adopted for adults has been sug-
gested by IDF for children, but its use is limited
because of the lack of population-specific reference
values (3). The problem is pressing considering the
increasing prevalence of the single components of
MS (4–6).
Non-alcoholic fatty liver disease (NAFLD) is the
most common chronic liver disease in Western
countries and includes a spectrum of alterations
ranging from steatosis to non-alcoholic steatohepa-
titis (NASH), fibrosis and liver cirrhosis (7,8). It is
associated with dyslipidaemia, obesity and insulin
resistance (IR), which are the main features of MS (9).
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A common feature of MS and NAFLD is the under-
lying IR condition. The liver fat content is increased
in subjects with MS and IR, independent of age,
gender and body fat distribution (7).
Association of metabolic
syndrome, insulin
resistance and
non-alcoholic fatty
liver disease
IR/MS and NAFLD are often associated. There is
increasing evidence suggesting that liver plays a
major role in the development of IR (10), but it is still
unclear whether the presence of liver involvement
could worse the metabolic risk in a patient with MS
or with IR alone (9). NAFLD is a predictor of the risk
of type 2 diabetes mellitus (10) and the insulin-
mediated suppression of hepatic glucose production
is impaired in children with NAFLD (11). In the first
stages of IR, insulin may continue to inhibit the
hepatic secretion of very-low density lipoproteins
(VLDLs) but, once the liver has become infiltrated
with fat, the overproduction of VLDL produces high
triglyceride and low HDL levels (12). Fatty liver is thus
a strong predictor of IR, as paradigmatically shown in
subjects with congenital or acquired lipodystrophies,
who are characterized by a redistribution of body fat
with concomitant liver steatosis and hypertriglyceri-
demia (13). Weaker and less convincing evidence
links NAFLD to cardiovascular disease (14). Accord-
ing to IDF, abdominal adiposity as detected by a
large waist circumference is needed to define MS (1).
This is done on the presumption that abdominal
adiposity plays a prominent role in the pathogenesis
of MS but the available evidence is far from being
conclusive in this respect (5). Whatever the case,
waist circumference allows an indirect estimate of
visceral fat depots and it is noteworthy that an
increased waist circumference has been found to be
associated with paediatric NASH (15–17). Through
the release of free fatty acids (FFAs) and adipocy-
tokines into portal circulation, visceral fat may be
responsible for some of the metabolic abnormalities
associated with fatty liver and obesity (18). In a recent
study, the quantity of diacylglycerol contained in lipid
droplets extracted from human livers was the strong-
est predictor of IR, explaining 64% of its variability
(19). Insulin binding to the high-affinity insulin recep-
tor (INSR) in hepatocytes leads to receptor auto-
phosphorylation and activation of INSR substrate-1
(IRS-1), IRS substrate-2 (IRS-2) and downstream
kinase AKT, which in turn phosphorylates the tran-
scription factor FOXO1 leading to decreased glucose
production and apoptosis (20,21). Liver-specific
deletion of INSR in mice causes hyperglycaemia and
liver failure (22), suggesting that hepatic IR promotes
liver damage not only by inducing metabolic altera-
tions but also by determining hepatocellular apopto-
sis, which is crucial in NASH progression (23). Insulin
may increase availability and oxidation of FFA leading
to hepatic steatosis by different mechanisms as
summarized in Fig. 1: (i) decreasing adipose tissue
lipolysis with consequent increase of FFA flux into
the liver; (ii) changing DNA-binding activity of sterol
regulatory element-binding protein 1c (SREBP-1c)
and peroxisome proliferator-activated receptor a
(PPAR-a) thus favouring lipogenesis as a conse-
quence of n-3 long-chain polyunsaturated fatty acid
(LCPUFA) depletion; and (iii) hyperinsulinaemia-
induced activation of lipogenic factor peroxisome
proliferator-activated receptor g (PPAR-g) (24). Inter-
estingly, supplementation of n-3 LCPUFA reduces
hepatic steatosis and IR in adults and children
(25,26).
↑VLDL secretion
↓lipolysis Insulin
↑FFA influx
↑VLDL
↑ de novo 
lipogenesis 
↑transcriptional 
activity of SREBP1 
and PPARs 
↓HDL 
↑HDL clearance
↓FFA efflux
↑β oxidation
PUFA 
depletion 
Lipid
accumulation
Figure 1 Peripheral insulin resistance may induce non-
alcoholic fatty liver disease by different mechanisms as
reported in the text. Insulin promotes intrahepatic lipid
accumulation by up-regulation of free fatty acid (FFA) influx
from adipocytes to hepatocytes, sterol regulatory element-
binding protein 1 (SREBP1) and peroxisome proliferator-
activated receptor (PPAR) transcriptional activity, b
oxidation and very-low density lipoprotein (VLDL) secre-
tion. HDL, high-density lipoprotein; PUFA, polyunsaturated
fatty acid.
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Activation of SREBP-1c increases the expression
of lipogenic genes such as acetyl-CoA carboxylase
1, fatty acid synthase and stearoyl-CoA desaturase 1
(27).
Moreover, PPAR-g co-activator (PGC)-1b, induced
in response to dietary intake of saturated fatty acids,
co-activates SREBP-1c to up-regulate de novo lipo-
genesis. Liver PPAR-g expression is increased in
animal models of fatty liver, and a liver-specific
knockout of PPAR-g prevents hepatic fat storage.
Adenovirus delivery of PPAR-g in hepatocytes results
in fatty liver, and PPAR-g interfering RNA reduces liver
triacylglycerol content. Moreover, increased expres-
sion of liver fatty acid translocase/CD36, a target
gene of PPAR-g, is associated with the development
of fatty liver. Finally, over-expression of adipose
differentiation-related protein, another target gene of
PPAR-g, increases triglyceride accumulation in rat
hepatocytes.
However, the IR/NAFLD association is not so clear-
cut as it may appear at first sight. For instance,
subjects with familial hypobetalipoproteinaemia have
high levels of intrahepatic triglycerides but their
hepatic and muscle sensitivities to insulin are similar
to those of healthy controls (28). Similar observations
have been reported in genetically obtained animal
models of fatty liver where neither the glucose nor the
insulin tolerance curves were altered despite the high
fat content of the liver (29). These findings indicate
that liver steatosis per se may not be causally linked
to IR, representing a marker rather than the cause of
metabolic dysfunctions (30).
Lipolysis of visceral fat produces an overload of
FFA in the portal system, which is considered the key
driver of hepatic IR and NAFLD (24). FFA and other
agents may lead to fatty liver and MS in different
ways according to the genetic and epigenetic back-
ground. Recently, endoplasmic factors have been
identified to play a major role in impairing hepatic
metabolism after a nutritional overload (31). N-3
LCPUFA acids, and especially docosahexaenoic
acid, may interact with cytoplasmic and transcrip-
tional factors regulating triglyceride accumulation
and lipid catabolism (26).
The role of adipose tissue
in insulin resistance,
metabolic syndrome
and non-alcoholic fatty
liver disease
IR is also closely associated with dys-regulated pro-
duction adipose tissue-derived circulating factors
called adipocytokines. Levels of adipokines guaran-
tee homeostasis of glucose and lipid metabolism,
but visceral obesity and excess of adipose tissue
greatly alter the adipocytokines balance, thus playing
a crucial role in the development of IR, MS and
NAFLD. Several adipocytokines, including leptin, adi-
ponectin, resistin, tumour necrosis factor (TNF)-
alpha and interleukin (IL)-6, have been involved in the
metabolic derangements that characterize MS and in
the histological damage observed in NAFLD (32,33).
Moreover, interestingly, in obese children the eleva-
tion of some adipocytokines (e.g. leptin, TNF-alpha
and IL-6) and hypoadiponectinemia may coexist as
markers of fat low-grade systemic inflammation
(34,35).
Hyperleptinaemia or leptin resistance has been
found associated with triglyceride accumulation in
liver, muscle and pancreas, resulting in the lipotoxic-
ity phenomenon that causes IR and steatosis and in
hyperinsulinaemic profile distinctive of MS in children
(36,37). Furthermore, according to the potential role
of leptin in inducing fibrosis (38), recently serum
levels of leptin have been reported, together with
caspase-cleaved CK18 fragments, as a good pre-
dictor of NASH and fibrosis in paediatric patients
with NAFLD (39).
Adiponectin, an antilipogenic and insulin-
sensitizing factor that is in contrast to other adipok-
ines, is expressed at low levels in serum in obese
subjects and in a variety of IR states, and it is con-
sidered as potential biomarker of MS in paediatric
population (37,40,41). In obese children, the reduc-
tion of circulating levels of adiponectin is considered
an early event in NAFLD that emerges also as
a stronger predictor of advanced liver steatosis
(42,43).
Although potential mechanisms involved in
decrease of adiponectin levels in subjects with IR
remain unclear, TNF-alpha could be a good candi-
date. In fact, the increase levels of TNF-alpha
in obese children could be responsible for the
associated hypoadiponectinemia (44). A recent
cross-sectional study conducted on 137 healthy pre-
pubertal children has highlighted that there is no
correlation between circulating levels of TNF-alpha
and IL-6 and the risk of cardiometabolic syndrome
(45). However, circulating TNF-alpha and IL-6 in
combination with the serum levels of endotoxin,
plasminogen activator inhibitor-1 results significantly
associated with severity of NAFLD in children (46).
Interestingly, recently it has been demonstrated that
the hepatic progenitor-dependent altered expression
of adiponectin, as well as that of resistin and
glucagon-like peptide 1, is strongly associated with
the severity of NAFLD in children (47).
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The role of the liver
Independent of a cause–effect relationship, liver
function and IR are closely related. Most of the bio-
chemical pathways involved in the pathogenesis of
MS are located in the liver, which can be considered
the ‘metabolic factory’ of MS (48,49). Once ectopic
fat accumulates in the liver, impaired glucose toler-
ance and hypertriglyceridemia will ensue, with
increased risk of type 2 diabetes (50). On the other
hand, the causal association between NAFLD and
cardiovascular disorders is much weaker (14).
Recently, Fabbrini et al. (51) studied obese subjects
categorized for high or low liver and visceral fat. They
found that high fat liver group was at higher risk of
developing metabolic deregulation. The authors'
conclusion was that intrahepatic triglyceride rather
than increased visceral adipose tissue (VAT) leads to
metabolic dysfunction in obese subjects. The same
group evaluated whether reducing VAT mass by sur-
gical removal of the omentum improves insulin sen-
sitivity and metabolic function in obese patients (52),
demonstrating that decreasing VAT through omen-
tectomy does not improve metabolic function in
obese patients. Overall, these observations suggest
that subjects able to displace fat from the liver would
be at lower risk of developing MS. Unfortunately,
because of the complex and still poor known patho-
genetic mechanisms leading to NAFLD, to date it is
very difficult to extrapolate data regarding possible
differences between the presence of simple steatosis
or NASH and the risk of MS (53). However, a recent
study conducted by the Non-alcoholic Steatohepa-
titis Clinical Research Network demonstrates that
some features of MS (particularly central obesity and
IR) associate with the histological patterns that define
NASH, including steatosis, ballooning and advanced
fibrosis, suggesting that MS traits should help iden-
tify subjects with more advanced disease or vice
versa NASH children could be more prone to
develop MS (54).
Within this context, the liver represents the meta-
bolic factor responsible, under certain conditions, for
many alterations associated with MS, and it is con-
ceivable that switching off this polluting factory may
interrupt some detrimental metabolic loops. Taken
together, these findings suggest that genetic factors,
epigenetic changes and unhealthy lifestyles may
contribute to liver susceptibility to fat accumulation
(49) (Fig. 2). It is conceivable that there are many
causes and types of fatty liver and that overnutrition
triggers most of them (55,56). Accordingly, NAFLD
may be the cause or effect of IR/MS on an individual
basis and, when NAFLD is the main cause of IR/MS,
it can be expected that therapies targeted at reduc-
ing liver fat storage may be successful in reducing
IR/MS (15). This can explain why the restoration of
insulin sensitivity does not always reverse NAFLD
(57). Longitudinal studies and randomized controlled
trials are needed to determine whether fatty liver is an
independent predictor of cardiometabolic risk and
whether its treatment could reduce the risk of cardi-
ometabolic disease. Because it is reasonable to
speculate that the sooner the intervention is, the
Genetic make-up Environment
VISCERAL OBESITY
Adipocyte IR
↑ FFA
IR predisposed 
genotype/phenotype
FATTY LIVER
↑Adipokine imbalance
↑Inflammation↑Oxidative stress
↑Inflammation ↑SREBP1
Hyperinsulinaemia
↑Glucose output
↓Glucose metabolic clearance
↓Reduced insulin sensitivity
↑FOXO1
↑PPARs
? OTFs
↑Hepatic cytokine release
Figure 2 Proposed flow chart that
explains the possible pathogenetic
correlation between some features
of metabolic syndrome and non-
alcoholic fatty liver disease. FFA, free
fatty acid; IR, insulin resistance;
OTFs, other transcription factors;
PPARs, peroxisome proliferator-
activated receptors; SREBP1,
sterol regulatory element-binding
protein 1.
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better the outcome would be, we believe that inter-
vention strategies in children and adolescents will
elucidate whether an ‘hepatometabolic syndrome’
really exists and the role of fatty liver as predictor of
cardiometabolic disease.
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